|
|
Volumn 303, Issue 11, 2010, Pages 1019-1020
|
|
Cancer therapy can be hard on the heart: Researchers aim to explain - and avoid - Cardiotoxicity
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
IMATINIB;
LAPATINIB;
SORAFENIB;
SULINDAC;
SUNITINIB;
TRASTUZUMAB;
CANCER CHEMOTHERAPY;
CANCER DIAGNOSIS;
CANCER PATIENT;
CANCER RADIOTHERAPY;
CANCER RESEARCH;
CANCER SCREENING;
CANCER SURVIVAL;
CANCER THERAPY;
CARDIOTOXICITY;
CARDIOVASCULAR RISK;
CONGESTIVE HEART FAILURE;
DRUG EFFECT;
HEART DISEASE;
HEART INFARCTION;
HUMAN;
HYPERLIPIDEMIA;
HYPERTENSION;
KIDNEY CARCINOMA;
METASTASIS;
NEOPLASM;
NONHUMAN;
PHYSICIAN;
PRIORITY JOURNAL;
RISK FACTOR;
SHORT SURVEY;
|
|
EID: 77949520286
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.2010.269 Document Type: Short Survey |
|
Times cited : (4)
|
|
References (0)
|
